Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 600 participants.
Also called NCT07033585
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose health services research
- Phase
- Phase 2/3
- Enrolled
- 600 participants
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Registry
-
NCT07033585
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07033585. Randomized; quadruple masking; primary purpose health services research. Start 2026-06-15 (actual); primary completion 2026-10-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
- Acronym
- GD-T2D
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- Intervention (Drug)
- China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Collaborator
- UnitedHealthcare
Record details
- Record id
cardio:ct-nct07033585- Content hash
8dfda6747df4bf8ed604bc641169ed20b69d80b022b419298dbe8a0e73e038e7